Enter a stock symbol
Enter a stock symbol to view that company's Altman Z-Score if it is a manufacturing company, or its Altman Z"-Score, if it is a non-financial, non-manufacturing company, and to view message board posts for that stock (Scores are available for premium members).
Screener
Below is a list of today's twenty-five most distressed stocks (according to their Altman Z-Score or Z''-Score, respectively) with a share price of $5 or higher. For details on how this ranking list is compiled, please click here.
Stock Chart
Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now
AFFX - This dog peaked in 2000
I have mentioned this company to friends as an example of the failure to innovate. Their flagship product (microarrays) is indeed superior but as a result of that, they haven't moved into the up and coming technology (next-generation sequencing), unlike their competitors (e.g. ILMN). They've recently made a couple of small acquisitions in an effort to provide some cash flow, but these are largely low-margin businesses of commodity molecular biology reagents. As I mentioned in the title, their stock peaked 10 years ago and has been waning ever since. Although they may not collapse as quickly as some other biotech brethren, the end is indeed coming.
Submit a comment
In order to comment please sign in.
After your recent long call (which I failed to act on, unfortunately, before the 50% move), I've got to give a closer look to your pharma ideas. Any chance this one might be bought out at a premium to its current price, or do you think that's not likely, in this case?
ILMN is looking a bit lofty itself, valuation-wise. Strong chart though.
I suspect that it will be bought out at some point (more for its IP than anything else), but that it will slide for a while longer. It would take a closer analysis of its financials than I'm really capable of doing. It came to my attention again yesterday when they tried to pitch us on some of their MB products. Really low-margin stuff that made me raise my eyebrows a bit and look at their stock price again. They've also had a lot of personnel turnover recently which is also not exactly a mark of health.